中图分类号R956 文献标志码A 文章编号 1001-0408(2025)14-1770-05

    DOI 10.6039/j.issn.1001-0408.2025.14.14

    ABSTRACTOBJECTIVEToevaluate thecost-efectivenessof finerenonecombinedwith standardofcare(SoC)inthe treatmentofheartfailurewithmildlyreducedejectionfraction(HFmrEF)orpreservedejectionfraction(HFpEF).METHODS BasedonaphaseIIclinical tial，a MarkovmodelwasconstructedfromtheperspectiveofChina’shealthcaresystemtocompare thetreatmentoutcomesoffinerenonecombinedwithSoCregimenversusSoCregimenaloneinthetreatmentofdiferentcardiac functionalstatusesofHFmrEF/HFpEF.Usingquality-adjustedlifeyear(QALY)asthehealthoutputindex，3times China’sper capita GDPin2023asthewilingnes-to-pay(WTP)threshold，asimulationwasconducted witha3-monthcyclelengthanda10- year time horizon，incorporating an annual discount rate of 5% .The dynamic changes across various stages of HFmrEF/HFpEF treatedwith finerenonecombinedwithSoCversusSoCaloneweresimulatedtoevaluatethelong-termefectivenessandcostsof the twotreatmentstrategies.Additionally，oe-waysensitivityanalysisndprobabilisticsnsitivityanalysswereperformed，totesthe robustnessof theresults.RESULTSTheicrementalcost-efectivenessratio(ICER)ofthefinerenonecombinedwith SoCregimen versusSoCregimenalonewas179504.75yuan/QALY ......